FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis
Frontiers in Pharmacology · 14.08.2025 · 16
DOI: 10.3389/fphar.2025.1584376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.08.2025. Verfasst von Xiaohui Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematologic malignancy with a high mortality rate and poor prognosis, largely attributed to the emergence of chemotherapy resistance. Cytarabine (Ara-C), the cornerstone chemotherapeutic agent for AML, faces significant challenges due to the development of resistance, creating an urgent need for novel therapeutic strategies. Pyroptosis as a new form of programmed cell death has emerged as a potential therapeutic target in tumor treatment. However, its role in overcoming Ara-C resistance in AML by modulating pyroptosis remains unexplored. FGFC1 (Fungi fibrinolytic compound 1) a natural compound derived from Stachybotrys longispora FG216, has previously been shown to have high efficacy against erlotinib-resistant non-small cell lung cancer, yet its effects on AML are unknown. This study demonstrated that FGFC1 overcame Ara-C resistance in AML by inducing apoptosis and pyroptosis. Mechanistically, FGFC1 induced mitochondrial dysfunction and the accumulation of intracellular reactive oxygen species (ROS), leading to the release of cytochrome c (Cyto-C), which activated Caspase-3 and triggered both apoptosis and pyroptosis. This process was driven by inhibition of the PI3K/Akt/mTOR signaling cascade, ultimately suppressing the growth of AML Ara-C-resistant cells. These findings highlight the potential of FGFC1 to overcome Ara-C resistance in AML, providing a promising therapeutic strategy for drug-resistant AML and supporting the broader application of marine-derived small molecules in cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
- Marine Biomedical Science and Technology Innovation Platform of Lin-gang Special Area, Shanghai, China.
- Department of Chemistry, College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
- Shanghai Engineering Research Center of Aquatic-Product Processing and Preservation, Shanghai, China.
Zitieren
APA
Hu, X., Li, Z., Zhou, R., Zhang, B., Wang, R., Li, T., Chang, J., Wu, W., & Liu, N. (2025). FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1584376
Vancouver
Hu X, Li Z, Zhou R, Zhang B, Wang R, Li T, et al. FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1584376
BibTeX
@article{Hu2025,
author = {Hu, Xiaohui and Li, Zhijian and Zhou, Rui and Zhang, Bing and Wang, Ruoxian and Li, Tongtong and Chang, Jiangcheng and Wu, Wenhui and Liu, Ning},
title = {FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1584376}
}
EUVIMED